Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Selley

Showing results (61-70 of 149) with videos related to

Pageof 15
Sort By:
RSC Medicinal Chemistry|January 22, 2021
Design and synthesis of a bivalent probe targeting the putative mu opioid receptor and chemokine receptor CXCR4 heterodimerBethany A Reinecke, Guifeng Kang, Yi Zheng, et al.
Biochemical Pharmacology|August 6, 2014
Delta FosB and AP-1-mediated transcription modulate cannabinoid CB₁ receptor signaling and desensitization in striatal and limbic brain regionsMatthew F Lazenka, Bethany G David, Aron H Lichtman, et al.
Biological Psychiatry|January 24, 2012
β-arrestin2 regulates cannabinoid CB1 receptor signaling and adaptation in a central nervous system region-dependent mannerPeter T Nguyen, Cullen L Schmid, Kirsten M Raehal, et al.
Molecular Pharmacology|March 31, 2006
Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptorSteven W Paugh, Michael P Cassidy, Hengjun He, et al.
Experimental Neurology|April 30, 2019
Gnal haploinsufficiency causes genomic instability and increased sensitivity to haloperidolMohammad Moshahid Khan, Jianfeng Xiao, T J Hollingsworth, et al.
Future Medicinal Chemistry|February 16, 2021
Exploring the putative mechanism of allosteric modulations by mixed-action kappa/mu opioid receptor bitopic modulatorsHuiqun Wang, Danni Cao, James C Gillespie, et al.
Neuropharmacology|August 19, 2008
Antipsychotic-induced alterations in CB1 receptor-mediated G-protein signaling and in vivo pharmacology in ratsJenny L Wiley, Seth H Kendler, James J Burston, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 16, 2013
Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effectsSteven G Kinsey, Laura E Wise, Divya Ramesh, et al.
Bioorganic & Medicinal Chemistry|September 24, 2013
Binding mode characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives via docking in opioid receptor crystal structures and site-directed mutagenesis studies: application of the 'message-address' concept in development of mu opioid receptor selective antagonistsSaheem A Zaidi, Christopher K Arnatt, Hengjun He, et al.
Neurochemical Research|January 1, 2016
Efficacy of Hybrid Tetrahydrobenzo[d]thiazole Based Aryl Piperazines D-264 and D-301 at D₂ and D₃ ReceptorsJuan Zhen, Tamara Antonio, Joanna C Jacob, et al.
Pageof 15

Showing results (61-70 of 149) with videos related to

Sort By:
Pageof 15
RSC Medicinal Chemistry|January 22, 2021
Design and synthesis of a bivalent probe targeting the putative mu opioid receptor and chemokine receptor CXCR4 heterodimerBethany A Reinecke, Guifeng Kang, Yi Zheng, et al.
Biochemical Pharmacology|August 6, 2014
Delta FosB and AP-1-mediated transcription modulate cannabinoid CB₁ receptor signaling and desensitization in striatal and limbic brain regionsMatthew F Lazenka, Bethany G David, Aron H Lichtman, et al.
Biological Psychiatry|January 24, 2012
β-arrestin2 regulates cannabinoid CB1 receptor signaling and adaptation in a central nervous system region-dependent mannerPeter T Nguyen, Cullen L Schmid, Kirsten M Raehal, et al.
Molecular Pharmacology|March 31, 2006
Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptorSteven W Paugh, Michael P Cassidy, Hengjun He, et al.
Experimental Neurology|April 30, 2019
Gnal haploinsufficiency causes genomic instability and increased sensitivity to haloperidolMohammad Moshahid Khan, Jianfeng Xiao, T J Hollingsworth, et al.
Future Medicinal Chemistry|February 16, 2021
Exploring the putative mechanism of allosteric modulations by mixed-action kappa/mu opioid receptor bitopic modulatorsHuiqun Wang, Danni Cao, James C Gillespie, et al.
Neuropharmacology|August 19, 2008
Antipsychotic-induced alterations in CB1 receptor-mediated G-protein signaling and in vivo pharmacology in ratsJenny L Wiley, Seth H Kendler, James J Burston, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 16, 2013
Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effectsSteven G Kinsey, Laura E Wise, Divya Ramesh, et al.
Bioorganic & Medicinal Chemistry|September 24, 2013
Binding mode characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives via docking in opioid receptor crystal structures and site-directed mutagenesis studies: application of the 'message-address' concept in development of mu opioid receptor selective antagonistsSaheem A Zaidi, Christopher K Arnatt, Hengjun He, et al.
Neurochemical Research|January 1, 2016
Efficacy of Hybrid Tetrahydrobenzo[d]thiazole Based Aryl Piperazines D-264 and D-301 at D₂ and D₃ ReceptorsJuan Zhen, Tamara Antonio, Joanna C Jacob, et al.
Pageof 15